第一条 为进一步规范塞力斯医疗科技集团股份有限公司（以下简称"公司"） 运行，充分维护中小股东的合法权益，根据《上市公司治理准则》等有关法律、 法规、规章、规范性文件及《塞力斯医疗科技集团股份有限公司章程》（以下简 称"《公司章程》"）的规定，特制订本实施细则。 第二条 公司股东会选举或更换董事时，适用本实施细则。 第三条 股东会就选举董事进行表决时，根据《公司章程》的规定或者股东 会的决议，可以实行累积投票制。若公司单一股东及其一致行动人拥有权益的股 份比例在 30%及以上以及公司选举 2 名以上独立董事的，应当采用累积投票制。 第四条 本实施细则所称的累积投票制度，是指股东会选举或更换董事有表 决权的每一股份拥有与拟选出的董事人数相同的表决权，股东既可以用所有的表 决权集中投票选举一人，也可以分散投票选举数人，每位股东持有的股份总数与 拟选董事人数的乘积为其合法拥有选举董事的投票权总数。 塞力斯医疗科技集团股份有限公司 累积投票实施细则 塞力斯医疗科技集团股份有限公司 累积投票实施细则 （2025 年 8 月） 第五条 股东会投票选举董事前，大会主持人应宣读累积投票制的说明，并 就股东对累积投票的相关问题 ...

塞力斯医疗科技集团股份有限公司 内部控制制度 塞力斯医疗科技集团股份有限公司 内部控制制度 （2025年8月） 第一章 总则 第一条 为加强塞力斯医疗科技集团股份有限公司（以下简称"公司"）内 部控制，促进公司规范运作和健康发展，保护投资者合法权益，根据《中华人 民共和国公司法》《中华人民共和国证券法》《上海证券交易所股票上市规则》 等法律法规的规定，结合公司的实际情况，制定本制度。 第二条 公司内部控制制度的目的： （一）遵守国家法律、法规、规章及其他相关规定； （二）提高公司经营的效益及效率，提升公司质量，增加对公司股东的回 报； （三）保障公司资产的安全、完整； （四）确保公司信息披露的真实、准确、完整和公平。 第三条 公司董事会应对公司内部控制制度的制定和有效执行负责。 第二章 内部控制的内容 第四条 公司的内部控制主要包括：环境控制、业务控制、会计系统控制、 信息传递控制、内部审计控制等内容。 第五条 公司应不断完善公司治理结构，确保董事会和股东会等机构合法运 作和科学决策，公司将逐步建立有效的激励约束机制，树立风险防范意识，培 育良好的企业精神和内部控制文化，创造全体职工充分了解并履行职责的环境。 ...

塞力斯医疗科技集团股份有限公司 内部审计制度 塞力斯医疗科技集团股份有限公司 内部审计制度 （2025年8月） 第一章 总则 第一条 为规范内部审计工作，明确内部审计机构和人员的职责，发挥内部 审计在强化内部控制、改善经营管理、提高经济效益中的作用，进一步促进塞力 斯医疗科技集团股份有限公司（以下简称"公司"）的自我完善和发展，实现内 部审计工作的制度化和规范化，根据《中华人民共和国审计法》《审计署关于内 部审计工作的规定》等相关法律法规、规章、规范性文件及《塞力斯医疗科技集 团股份有限公司章程》（以下简称"《公司章程》"），特制定本制度。 第二条 本制度所称内部审计指公司内部审计机构或内部审计人员，依据国 家有关法律法规和本制度的规定，对公司内部控制和风险管理的有效性、财务信 息的真实性和完整性以及经营活动的效率和效果等开展的一种评价活动。 第三条 内部审计机构和内部审计人员在审计委员会的领导下，独立、客观 地行使职权，对审计委员会负责。 内部审计部门应当保持独立性，不得置于财务部门的领导之下，或者与财务 部门合署办公。 第二章 内部审计机构和内部审计人员 第九条 内部审计人员按内部审计程序开展工作，对内部 ...

塞力斯医疗科技集团股份有限公司 募集资金管理办法 塞力斯医疗科技集团股份有限公司 募集资金管理办法 （2025 年 8 月） 第一章 总则 第一条 为完善塞力斯医疗科技集团股份有限公司（以下简称"公司"）治 理，规范公司对募集资金的使用和管理，提高募集资金的使用效率和效益，根据 《中华人民共和国公司法》《中华人民共和国证券法》（以下简称"《证券法》"）、 《上市公司募集资金监管规则》《上海证券交易所股票上市规则》《上海证券交 易所上市公司自律监管指引第 1 号——规范运作》等法律法规、规章、规范性文 件及《塞力斯医疗科技集团股份有限公司章程》（以下简称"《公司章程》"） 的规定，制定本办法。 第二条 本办法所称募集资金是指公司通过发行股票或者其他具有权益性质 的证券，向投资者募集并用于特定用途的资金，但不包括公司实施股权激励计划 募集的资金。 本办法所称超募资金是指实际募集资金净额超过计划募集资金金额的部分。 第三条 公司应建立并完善募集资金存放、管理、使用、改变用途、监督和 责任追究的内部控制制度，明确募集资金使用的分级审批权限、决策程序、风险 控制措施及信息披露要求，规范使用募集资金。 公司董事会应当持续 ...

塞力斯医疗科技集团股份有限公司 信息披露暂缓与豁免管理制度 塞力斯医疗科技集团股份有限公司 信息披露暂缓与豁免管理制度 （2025 年 8 月） 第一条 为了规范塞力斯医疗科技集团股份有限公司（以下简称"公司"） 信息披露暂缓与豁免行为，明确公司及相关信息披露义务人依法合规履行信息 披露义务，保护投资者的合法权益，根据《中华人民共和国公司法》《中华人 民共和国证券法》《上市公司信息披露暂缓与豁免管理规定》《上海证券交易 所股票上市规则》等法律法规、规章、规范性文件以及《塞力斯医疗科技集团 股份有限公司章程》（以下简称"《公司章程》"）等的规定，制定本制度。 第二条 公司及其他信息披露义务人暂缓、豁免披露临时报告，在定期报 告、临时报告中豁免披露中国证券监督管理委员会（以下简称"中国证监会"） 和证券交易所规定或者要求披露的内容，适用本制度。 第三条 公司和其他信息披露义务人应当真实、准确、完整、及时、公平 地披露信息，不得滥用暂缓或者豁免披露规避信息披露义务、误导投资者，不 得实施内幕交易、操纵市场等违法行为。 第七条 公司和其他信息披露义务人拟披露的信息涉及商业秘密或者保密 商务信息（以下统称"商业秘密"） ...

塞力斯医疗科技集团股份有限公司 融资管理制度 塞力斯医疗科技集团股份有限公司 融资管理制度 （2025 年 8 月） 第一章 总则 第一条 为规范塞力斯医疗科技集团股份有限公司（以下称"公司"）的融资 行为，加强融资管理和财务监控，降低融资成本，有效防范财务风险，维护股份 公司和投资者合法权益，根据相关法律法规，结合公司实际情况，特制定本制度。 第二条 本制度适用于公司及其下属各独立核算的全资子公司和控股子公司 （以下简称"子公司"），参股公司参照执行。其中，除股份公司外通称权属公司。 第三条 本制度中所称融资，仅指债务性融资，不包括权益性融资（即对外 投资）。债务性融资是指融资结束后增加了企业负债的融资，如向银行或非银行 金融机构借款、发行企业债券、融资租赁等。权益性融资是指融资结束后增加了 企业权益资本的融资，如追加资本金、增资扩股、发行股票。 第四条 融资活动应符合公司中长期战略发展规划。其原则为： （一）总体上以满足企业资金需要为宜，但要遵从公司的统筹安排； （二）充分利用各级政府及行业优惠政策，积极争取低成本融资如：无偿、 资助、无息或贴息贷款等； 第二章 融资活动内部控制的目标 第五条 融资活动内 ...

[Important Notice](index=2&type=section&id=%E9%87%8D%E8%A6%81%E6%8F%90%E7%A4%BA) This section outlines key declarations by the board, supervisors, and management, along with risk warnings and the audit status of the report [I. Statement by the Board of Directors, Supervisory Board, and Senior Management](index=2&type=section&id=%E4%B8%80%E3%80%81%E6%9C%AC%E5%85%AC%E5%8F%B8%E8%91%A3%E4%BA%8B%E4%BC%9A%E3%80%81%E7%9B%91%E4%BA%8B%E4%BC%9A%E5%8F%8A%E8%91%A3%E4%BA%8B%E3%80%81%E7%9B%91%E4%BA%8B%E3%80%81%E9%AB%98%E7%BA%A7%E7%AE%A1%E7%90%86%E4%BA%BA%E5%91%98%E4%BF%9D%E8%AF%81%E5%8D%8A%E5%B9%B4%E5%BA%A6%E6%8A%A5%E5%91%8A%E5%86%85%E5%AE%B9%E7%9A%84%E7%9C%9F%E5%AE%9E%E6%80%A7%E3%80%81%E5%87%86%E7%A1%AE%E6%80%A7%E3%80%81%E5%AE%8C%E6%95%B4%E6%80%A7%EF%BC%8C%E4%B8%8D%E5%AD%98%E5%9C%A8%E8%99%9A%E5%81%87%E8%AE%B0%E8%BD%BD%E3%80%81%E8%AF%AF%E5%AF%BC%E6%80%A7%E9%99%88%E8%BF%B0%E6%88%96%E9%87%8D%E5%A4%A7%E9%81%97%E6%BC%8F%EF%BC%8C%E5%B9%B6%E6%89%BF%E6%8B%85%E4%B8%AA%E5%88%AB%E5%92%8C%E8%BF%9E%E5%B8%A6%E7%9A%84%E6%B3%95%E5%BE%8B%E8%B4%A3%E4%BB%BB%E3%80%82) The Board, Supervisory Board, and senior management guarantee the report's truthfulness, accuracy, and completeness, assuming legal responsibility - The Board, Supervisory Board, and senior management guarantee the report's truthfulness, accuracy, and completeness[3](index=3&type=chunk) [II. All Directors Attended the Board Meeting](index=2&type=section&id=%E4%BA%8C%E3%80%81%E5%85%AC%E5%8F%B8%E5%85%A8%E4%BD%93%E8%91%A3%E4%BA%8B%E5%87%BA%E5%B8%AD%E8%91%A3%E4%BA%8B%E4%BC%9A%E4%BC%9A%E8%AE%AE%E3%80%82) All company directors attended the Board of Directors meeting - All directors attended the Board of Directors meeting[4](index=4&type=chunk) [III. This Semi-Annual Report is Unaudited](index=2&type=section&id=%E4%B8%89%E3%80%81%E6%9C%AC%E5%8D%8A%E5%B9%B4%E5%BA%A6%E6%8A%A5%E5%91%8A%E6%9C%AA%E7%BB%8F%E5%AE%A1%E8%AE%A1%E3%80%82) This semi-annual report has not been audited - The report is unaudited[5](index=5&type=chunk) [IV. Statement by Company Head and Head of Accounting Department](index=2&type=section&id=%E5%9B%9B%E3%80%81%E5%85%AC%E5%8F%B8%E8%B4%9F%E8%B4%A3%E4%BA%BA%E6%B8%A9%E4%BC%9F%E3%80%81%E4%B8%BB%E7%AE%A1%E4%BC%9A%E8%AE%A1%E5%B7%A5%E4%BD%9C%E8%B4%9F%E8%B4%A3%E4%BA%BA%E6%B2%88%E7%87%95%E5%8F%8A%E4%BC%9A%E8%AE%A1%E6%9C%BA%E6%9E%84%E8%B4%9F%E8%B4%A3%E4%BA%BA%EF%BC%88%E4%BC%9A%E8%AE%A1%E4%B8%BB%E7%AE%A1%E4%BA%BA%E5%91%98%EF%BC%89%E9%BB%84%E6%80%9D%E7%87%95%E5%A3%B0%E6%98%8E%EF%BC%9A%E4%BF%9D%E8%AF%81%E5%8D%8A%E5%B9%B4%E5%BA%A6%E6%8A%A5%E5%91%8A%E4%B8%AD%E8%B4%A2%E5%8A%A1%E6%8A%A5%E5%91%8A%E7%9A%84%E7%9C%9F%E5%AE%9E%E3%80%81%E5%87%86%E7%A1%AE%E3%80%81%E5%AE%8C%E6%95%B4%E3%80%82) The company head and accounting department heads declare the financial report's truthfulness, accuracy, and completeness - Company Head Wen Wei, Chief Accountant Shen Yan, and Head of Accounting Department Huang Siyan declare the financial report is true, accurate, and complete[5](index=5&type=chunk) [V. Profit Distribution Plan or Capital Reserve to Share Capital Increase Plan Approved by the Board of Directors for This Reporting Period](index=2&type=section&id=%E4%BA%94%E3%80%81%E8%91%A3%E4%BA%8B%E4%BC%9A%E5%86%B3%E8%AE%AE%E9%80%9A%E8%BF%87%E7%9A%84%E6%9C%AC%E6%8A%A5%E5%91%8A%E6%9C%9F%E5%88%A9%E6%B6%A6%E5%88%86%E9%85%8D%E9%A2%84%E6%A1%88%E6%88%96%E5%85%AC%E7%A7%AF%E9%87%91%E8%BD%AC%E5%A2%9E%E8%82%A1%E6%9C%AC%E9%A2%84%E6%A1%88) There is no profit distribution or capital reserve to share capital increase plan for this reporting period - No profit distribution or capital reserve to share capital increase plan[6](index=6&type=chunk) [VI. Risk Statement Regarding Forward-Looking Statements](index=2&type=section&id=%E5%85%AD%E3%80%81%E5%89%8D%E7%9E%BB%E6%80%A7%E9%99%88%E8%BF%B0%E7%9A%84%E9%A3%8E%E9%99%A9%E5%A3%B0%E6%98%8E) Forward-looking statements in the report do not constitute a substantive commitment, cautioning investors about investment risks - Forward-looking statements do not constitute a substantive commitment, cautioning investment risks[6](index=6&type=chunk) [VII. Non-Operating Funds Occupied by Controlling Shareholder and Other Related Parties](index=2&type=section&id=%E4%B8%83%E3%80%81%E6%98%AF%E5%90%A6%E5%AD%98%E5%9C%A8%E8%A2%AB%E6%8E%A7%E8%82%A1%E8%82%A1%E4%B8%9C%E5%8F%8A%E5%85%B6%E4%BB%96%E5%85%B3%E8%81%94%E6%96%B9%E9%9D%9E%E7%BB%8F%E8%90%A5%E6%80%A7%E5%8D%A0%E7%94%A8%E8%B5%84%E9%87%91%E6%83%85%E5%86%B5) There is no non-operating occupation of funds by controlling shareholders or other related parties - No non-operating occupation of funds[7](index=7&type=chunk) [VIII. External Guarantees Provided in Violation of Decision-Making Procedures](index=2&type=section&id=%E5%85%AB%E3%80%81%E6%98%AF%E5%90%A6%E5%AD%98%E5%9C%A8%E8%BF%9D%E5%8F%8D%E8%A7%84%E5%AE%9A%E5%86%B3%E7%AD%96%E7%A8%8B%E5%BA%8F%E5%AF%B9%E5%A4%96%E6%8F%90%E4%BE%9B%E6%8B%85%E4%BF%9D%E7%9A%84%E6%83%85%E5%86%B5) There are no external guarantees provided in violation of decision-making procedures - No external guarantees provided in violation of decision-making procedures[7](index=7&type=chunk) [IX. Whether More Than Half of the Directors Cannot Guarantee the Truthfulness, Accuracy, and Completeness of the Company's Disclosed Semi-Annual Report](index=2&type=section&id=%E4%B9%9D%E3%80%81%E6%98%AF%E5%90%A6%E5%AD%98%E5%9C%A8%E5%8D%8A%E6%95%B0%E4%BB%A5%E4%B8%8A%E8%91%A3%E4%BA%8B%E6%97%A0%E6%B3%95%E4%BF%9D%E8%AF%81%E5%85%AC%E5%8F%B8%E6%89%80%E6%8A%AB%E9%9C%B2%E5%8D%8A%E5%B9%B4%E5%BA%A6%E6%8A%A5%E5%91%8A%E7%9A%84%E7%9C%9F%E5%AE%9E%E6%80%A7%E3%80%81%E5%87%86%E7%A1%AE%E6%80%A7%E5%92%8C%E5%AE%8C%E6%95%B4%E6%80%A7) There is no situation where more than half of the directors cannot guarantee the report's truthfulness, accuracy, and completeness - No situation where more than half of the directors cannot guarantee the report's truthfulness, accuracy, and completeness[7](index=7&type=chunk) [X. Major Risk Warning](index=2&type=section&id=%E5%8D%81%E3%80%81%E9%87%8D%E5%A4%A7%E9%A3%8E%E9%99%A9%E6%8F%90%E7%A4%BA) Major risks are detailed in Section III, "Management Discussion and Analysis," Subsection V, "(I) Potential Risks" - Major risk warnings are detailed in Section III, 'Management Discussion and Analysis,' Subsection V, '(I) Potential Risks'[7](index=7&type=chunk) [Section I Definitions](index=4&type=section&id=%E7%AC%AC%E4%B8%80%E8%8A%82%20%E9%87%8A%E4%B9%89) This section provides definitions for key terms used throughout the report [Section II Company Profile and Key Financial Indicators](index=7&type=section&id=%E7%AC%AC%E4%BA%8C%E8%8A%82%20%E5%85%AC%E5%8F%B8%E7%AE%80%E4%BB%8B%E5%92%8C%E4%B8%BB%E8%A6%81%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87) This section presents the company's basic information and a summary of its key financial performance and indicators [I. Company Information](index=7&type=section&id=%E4%B8%80%E3%80%81%E5%85%AC%E5%8F%B8%E4%BF%A1%E6%81%AF) This section outlines basic registration details, legal representative, and company abbreviation for Saily Medical - Company Chinese Name: **Saily Medical Technology Group Co., Ltd**[17](index=17&type=chunk) - Company Chinese Abbreviation: **Saily Medical**[17](index=17&type=chunk) - Legal Representative: **Wen Wei**[17](index=17&type=chunk) [II. Contact Person and Information](index=7&type=section&id=%E4%BA%8C%E3%80%81%E8%81%94%E7%B3%BB%E4%BA%BA%E5%92%8C%E8%81%94%E7%B3%BB%E6%96%B9%E5%BC%8F) This section provides contact details for the company's Board Secretary, including address, phone, fax, and email - Board Secretary: **Fan Li**[18](index=18&type=chunk) - Contact Number: **027-83386020**[18](index=18&type=chunk) [III. Brief Introduction to Changes in Basic Information](index=7&type=section&id=%E4%B8%89%E3%80%81%E5%9F%BA%E6%9C%AC%E6%83%85%E5%86%B5%E5%8F%98%E6%9B%B4%E7%AE%80%E4%BB%8B) This section details changes in the company's registered and office addresses, along with its website and email - Company Registered Address: **No. 1310 Jinshan Avenue, Dongxihu District, Wuhan City**[19](index=19&type=chunk) - Company Website: **www.thalys.net.cn**[19](index=19&type=chunk) [IV. Brief Introduction to Changes in Information Disclosure and Document Storage Locations](index=8&type=section&id=%E5%9B%9B%E3%80%81%E4%BF%A1%E6%81%AF%E6%8A%AB%E9%9C%B2%E5%8F%8A%E5%A4%87%E7%BD%AE%E5%9C%B0%E7%82%B9%E5%8F%98%E6%9B%B4%E6%83%85%E5%86%B5%E7%AE%80%E4%BB%8B) This section lists the designated newspapers for information disclosure, the website for semi-annual reports, and the report's storage location - Information Disclosure Newspapers: **China Securities Journal, Shanghai Securities News, Securities Daily, Securities Times**[20](index=20&type=chunk) - Website for Semi-Annual Report: **www.sse.com.cn**[20](index=20&type=chunk) [V. Company Stock Profile](index=8&type=section&id=%E4%BA%94%E3%80%81%E5%85%AC%E5%8F%B8%E8%82%A1%E7%A5%A8%E7%AE%80%E5%86%B5) This section provides details on the company's A-share stock, including listing exchange, stock abbreviation, and stock code - Stock Type: **A-share**[21](index=21&type=chunk) - Stock Exchange: **Shanghai Stock Exchange**[21](index=21&type=chunk) - Stock Code: **603716**[21](index=21&type=chunk) [VII. Company's Key Accounting Data and Financial Indicators](index=8&type=section&id=%E4%B8%83%E3%80%81%E5%85%AC%E5%8F%B8%E4%B8%BB%E8%A6%81%E4%BC%9A%E8%AE%A1%E6%95%B0%E6%8D%AE%E5%92%8C%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87) This section discloses key accounting data and financial indicators for the reporting period (January-June 2025), explaining reasons for revenue and net profit decline Key Accounting Data (Jan-Jun 2025 vs. Prior Year Period) | Indicator | Current Period (Jan-Jun) (CNY) | Prior Year Period (CNY) | Change (%) | | :--- | :--- | :--- | :--- | | Operating Revenue | 583,500,840.55 | 975,687,565.49 | -40.20 | | Total Profit | -51,926,111.52 | 13,120,757.82 | -495.76 | | Net Profit Attributable to Shareholders of Listed Company | -56,119,215.09 | -4,772,497.51 | N/A | | Net Cash Flow from Operating Activities | -79,169,044.62 | -48,877,944.40 | N/A | | Net Assets Attributable to Shareholders of Listed Company (Period-end) | 876,660,040.59 | 934,292,086.63 | -6.17 | | Total Assets (Period-end) | 2,199,028,725.29 | 2,830,070,456.98 | -22.30 | Key Financial Indicators (Jan-Jun 2025 vs. Prior Year Period) | Indicator | Current Period (Jan-Jun) | Prior Year Period | Change (%) | | :--- | :--- | :--- | :--- | | Basic Earnings Per Share (CNY/share) | -0.29 | -0.02 | N/A | | Diluted Earnings Per Share (CNY/share) | -0.29 | -0.02 | N/A | | Weighted Average Return on Net Assets (%) | -6.73 | -0.43 | Decreased by 6.3 percentage points | - Operating revenue decreased by **40.20%**, primarily due to the transfer of some subsidiary equity (reducing revenue by **CNY 248 million**) and strategic transformation, along with industry policy impacts leading to non-renewal of some businesses[25](index=25&type=chunk) - Net profit attributable to shareholders of the listed company was **CNY -56.12 million**, a year-on-year decrease of **CNY 51.35 million**, mainly affected by declining operating revenue, increased strategic R&D investment, and higher credit impairment losses[25](index=25&type=chunk)[26](index=26&type=chunk) [IX. Non-Recurring Gains and Losses Items and Amounts](index=9&type=section&id=%E4%B9%9D%E3%80%81%E9%9D%9E%E5%B8%B8%E8%A7%84%E6%80%A7%E6%8D%9F%E7%9B%8A%E9%A1%B9%E7%9B%AE%E5%92%8C%E9%87%91%E9%A2%9D) This section lists non-recurring gains and losses items and their amounts for the reporting period, totaling CNY 14.48 million - Disposal gains/losses on non-current assets: **CNY 13.71 million**[28](index=28&type=chunk) - Government grants recognized in current profit/loss: **CNY 0.95 million**[28](index=28&type=chunk) - Total non-recurring gains and losses: **CNY 14.48 million**[29](index=29&type=chunk) [Section III Management Discussion and Analysis](index=11&type=section&id=%E7%AC%AC%E4%B8%89%E8%8A%82%20%E7%AE%A1%E7%90%86%E5%B1%82%E8%AE%A8%E8%AE%BA%E4%B8%8E%E5%88%86%E6%9E%90) This section provides an in-depth discussion and analysis of the company's operations, financial performance, and strategic outlook [I. Explanation of the Company's Industry and Main Business During the Reporting Period](index=11&type=section&id=%E4%B8%80%E3%80%81%E6%8A%A5%E5%91%8A%E6%9C%9F%E5%86%85%E5%85%AC%E5%8F%B8%E6%89%80%E5%B1%9E%E8%A1%8C%E4%B8%9A%E5%8F%8A%E4%B8%BB%E8%90%A5%E4%B8%9A%E5%8A%A1%E6%83%85%E5%86%B5%E8%AF%B4%E6%98%8E) This section details the company's industry, macro environment, policy guidance, market challenges, and business layout in SPD+IVD+Regional Inspection, AI medical, and global innovation - China's healthcare industry is steadily growing, driven by increased health awareness, accelerated aging, and policy support, with the market size expected to approach **CNY 2.4 trillion** by **2029**, at a **16%** compound annual growth rate[32](index=32&type=chunk)[34](index=34&type=chunk) - National-level "AI+medical" policies are intensively introduced, upgrading smart healthcare from "pilot encouragement" to "systematic implementation," emphasizing localization and data security[33](index=33&type=chunk) - SPD project penetration in national medical institutions rose to approximately **21.5%**, with the market size expected to grow by **2%** for the full year **2025**[37](index=37&type=chunk) [(I) Industry Overview During the Reporting Period](index=11&type=section&id=%28%E4%B8%80%29%20%E6%8A%A5%E5%91%8A%E6%9C%9F%E5%86%85%E5%85%AC%E5%8F%B8%E6%89%80%E5%A4%84%E8%A1%8C%E4%B8%9A%E6%83%85%E5%86%B5) This section outlines China's healthcare industry growth amid complex economic conditions, highlighting AI+medical policies, deepened medical insurance reform, and market outlook - China's healthcare expenditure continues to expand, with its share of GDP increasing annually, driven by an aging population and policy support[32](index=32&type=chunk) - AI+medical policies are systematically implemented, covering high-frequency scenarios like AI diagnosis, smart medication, and medical insurance settlement, and are included in the green channel for innovative medical devices[33](index=33&type=chunk) - Deepening medical insurance reform, normalized volume-based procurement squeezes profits, and DRG/DIP payment reform drives refined operations[34](index=34&type=chunk) - China's medical device industry market size is projected to approach **CNY 2.4 trillion** by **2029**, with a compound annual growth rate of **16%**[34](index=34&type=chunk) [(II) Business Operations During the Reporting Period](index=14&type=section&id=%28%E4%BA%8C%29%20%E6%8A%A5%E5%91%8A%E6%9C%9F%E5%86%85%E5%85%AC%E5%8F%B8%E4%BB%8E%E4%BA%8B%E7%9A%84%E4%B8%9A%E5%8A%A1%E6%83%85%E5%86%B5) This section details Saily Medical's business progress in SPD+IVD+Regional Inspection, AI medical, and global innovation technology development - SPD+IVD+Regional Inspection Collaborative Construction: Seizing regional medical reform opportunities, SPD lean management, IVD collectivization, and regional inspection collaboration are synergistically developing, with projects in Chongqing Bishan, Jiangsu Yixing, Tongxiang, Lianzhou, and other areas steadily entering the harvest period[46](index=46&type=chunk)[47](index=47&type=chunk) - AI Medical Forward-Looking Layout: Centered on "AI+Medical Big Data," building comprehensive smart hospital solutions, self-developed SPD operation software system passed multiple authoritative certifications, hardware equipment achieved localization; deployed "Mental Illness Full-Course Digital Intelligence System—Haisilingxi," collaborating with Huawei and the National Key Laboratory of Brain-Computer Intelligence to advance brain science large models in psychiatry; as the second largest shareholder of Wuhan Jindou Medical, collaborated with DeepSeek to build "Medical Big Data–Specialized Disease Large Model-Clinical Decision Support Products," reshaping disease diagnosis and treatment management services; co-built "Automated Antimicrobial Susceptibility Testing Platform + Smart AI Large Model Antimicrobial Susceptibility Diagnosis and Treatment System" with Shanghai Huashan Hospital, achieving a closed-loop for antimicrobial susceptibility testing[50](index=50&type=chunk)[51](index=51&type=chunk)[55](index=55&type=chunk)[58](index=58&type=chunk)[61](index=61&type=chunk) - Global Innovative Technology Multi-Track Collaborative Development: Wholly-owned subsidiary Saily Bio, driven by "technology export" and "domestic intelligent manufacturing," has deployed its coagulation assembly line ParthenON LAS and related projects in 5 core laboratories under KingMed Diagnostics; invested in Inflammatix, whose TriVerity™ detection system (Myrna™ instrument and reagents) has received FDA approval, with significant localization progress, and the Myrna™ instrument platform largely localized; introduced GA-map® detection products, open to C-end consumers, building a complete ecosystem from drug discovery to consumer gut health services; associate company Kangda Xingjian approved as a foreign-invested gene and cell therapy technology enterprise, introducing LevitasBio's LeviCell® label-free magnetophoretic cell separation and enrichment technology, reducing domestic chip costs by nearly **90%**; introduced Italy's OMPECO's Friction Heat (FHT) technology, collaborating with CCIC Shenzhen and Southern University of Science and Technology on a special research project "AI Big Data Driven RDF Zero-Waste City"; partnered with Italy's COPAN to co-build the WASPLab National Exhibition Center, introducing the first domestic microbial AI identification system and fully automated microbial assembly line; strategically invested in ATRQβ-001, the world's first therapeutic antihypertensive vaccine, with IND application submitted and Phase I clinical trials expected to start in the second half of **2025**[62](index=62&type=chunk)[63](index=63&type=chunk)[65](index=65&type=chunk)[66](index=66&type=chunk)[68](index=68&type=chunk)[69](index=69&type=chunk)[70](index=70&type=chunk)[72](index=72&type=chunk)[77](index=77&type=chunk)[79](index=79&type=chunk)[80](index=80&type=chunk) [II. Discussion and Analysis of Operations](index=22&type=section&id=%E4%BA%8C%E3%80%81%E7%BB%8F%E8%90%A5%E6%83%85%E5%86%B5%E7%9A%84%E8%AE%A8%E8%AE%BA%E4%B8%8E%E5%88%86%E6%9E%90) This section summarizes the company's operating strategies and achievements in H1 2025, focusing on smart healthcare, strategic transformation, SPD upgrades, and asset optimization - The company adheres to its mission of "Innovating for a Healthy China," advancing its core strategy of "Broad Market + Regionalized Model + AI-Driven"[81](index=81&type=chunk) - Establishing a three-tier strategic matrix: Wuhan Headquarters (SPD/IVD collectivization, regional inspection), Shanghai Headquarters (critical illness AI in vitro diagnostics, life science technology transformation), and Chengdu Region (precision medical diagnostics)[81](index=81&type=chunk) - To focus on core segments, the company transferred equity in some subsidiaries (Wuhan Huixin, Aksu Yonglin, Inner Mongolia Saily) in **2024** and early **2025**, recovering funds[82](index=82&type=chunk) [(I) Further Focus on Smart Healthcare, Accelerating Strategic Transformation of Asset Operations](index=22&type=section&id=%28%E4%B8%80%29%20%E8%BF%9B%E4%B8%80%E6%AD%A5%E8%81%9A%E7%84%A6%E6%99%BA%E6%85%A7%E5%8C%BB%E7%96%97%EF%BC%8C%E5%8A%A0%E9%80%9F%E6%8E%A8%E8%BF%9B%E8%B5%84%E4%BA%A7%E8%BF%90%E8%90%A5%E6%88%98%E7%95%A5%E8%BD%AC%E5%9E%8B) The company continues to transform traditional medical services towards refined and smart healthcare, strategically deploying AI in diverse scenarios - The company is committed to becoming a leading domestic "AI+Medical Big Data" smart healthcare service provider[83](index=83&type=chunk) - Focusing on R&D of intelligent diagnostic products, digital therapy development, breaking through frontier areas such as brain science large models, rare disease/critical illness specialized models, and microbial drug resistance diagnosis and treatment prediction models[83](index=83&type=chunk) - Extending AI technology to innovative scenarios such as smart "zero-waste" city solutions and zero-waste industrial parks[83](index=83&type=chunk) [(II) Deepening Smart SPD Upgrades, Strengthening Technology Innovation Layout](index=22&type=section&id=%28%E4%BA%8C%29%20%E6%B7%B1%E8%80%95%E6%99%BA%E6%85%A7SPD%E5%8D%87%E7%BA%A7%EF%BC%8C%E5%BC%BA%E5%8C%96%E6%8A%80%E6%9C%AF%E5%88%9B%E6%96%B0%E5%B8%83%E5%B1%80) The company is upgrading traditional SPD to "Smart SPD" by integrating IoT, AI, and blockchain, while also advancing technology innovation and localization - Promoting "Smart SPD" upgrades, integrating frontier technologies such as IoT (RFID/HarmonyOS ecosystem), AI (consumable demand forecasting), and blockchain (traceability and anti-counterfeiting)[84](index=84&type=chunk) - Strategic cooperation with Huawei, developing customized software solutions based on open-source databases, creating a full-chain secure solution for "data collection-storage-analysis"[84](index=84&type=chunk) - Participating in the localization R&D of microbial assembly line WPS-XPS and TriVerity™ detection systems, enhancing intelligence and diagnostic accuracy[85](index=85&type=chunk) [(III) Optimizing Assets and Operations, Solidifying the Foundation for Innovative Development](index=23&type=section&id=%28%E4%B8%89%29%20%E4%BC%98%E5%8C%96%E8%B5%84%E4%BA%A7%E4%B8%8E%E8%BF%90%E8%90%A5%EF%BC%8C%E5%A0%AF%E5%AE%9E%E5%88%9B%E6%96%B0%E5%8F%91%E5%B1%95%E6%A0%B9%E5%9F%BA) The company focuses on core businesses, divesting underperforming subsidiaries, optimizing resource allocation, enhancing synergy, and controlling costs while increasing R&D investment - Divesting subsidiaries with low relevance to core business and poor performance (e.g., Wuhan Huixin, Aksu Yonglin, Inner Mongolia Saily), recovering funds to focus on core segments[86](index=86&type=chunk) - Significant achievements in cost control, with total administrative, selling, and financial expenses decreasing by **9.40%** compared to H1 **2024**[86](index=86&type=chunk) - Continuously increasing R&D investment in independent R&D of in vitro diagnostic reagents, medical IoT applications, medical big data analysis platforms, and industrialization of overseas innovative technologies[86](index=86&type=chunk) [III. Analysis of Core Competencies During the Reporting Period](index=23&type=section&id=%E4%B8%89%E3%80%81%E6%8A%A5%E5%91%8A%E6%9C%9F%E5%86%85%E6%A0%B8%E5%BF%83%E7%AB%9E%E4%BA%89%E5%8A%9B%E5%88%86%E6%9E%90) This section analyzes the company's core competencies, including strong medical informatization R&D, advanced overseas technology integration, forward-looking multi-track strategy, and robust customer and data resource integration - Strong medical informatization R&D capabilities: Independently developed SPD software, combining HarmonyOS computing power with Dameng database, forming "localized, secure, and controllable" technological features, and building a "technologically independent and controllable + ecological collaborative evolution" security alliance with Huawei, Kylinsoft, etc[87](index=87&type=chunk)[88](index=88&type=chunk) - Introduction and transformation of advanced overseas technologies: Introducing advanced foreign life science and molecular diagnostic technologies, achieving localized substitution through technology transfer, such as the TriVerity™ acute infection and sepsis detection system[89](index=89&type=chunk) - Forward-looking multi-pronged strategic layout: Deeply cultivated in the medical supply chain for over two decades, first to upgrade to SPD operation mode, building a first-mover advantage, and deploying AI medical technology for multi-track collaborative development[90](index=90&type=chunk) - High-quality customer and data resource integration capabilities: Possessing numerous renowned medical institution clients nationwide, collaborating with top medical institutions to develop AI digital diagnosis and treatment and data analysis models, such as the "Haisilingxi" human-computer dialogue psychotherapist[91](index=91&type=chunk) [IV. Main Operating Performance During the Reporting Period](index=25&type=section&id=%E5%9B%9B%E3%80%81%E6%8A%A5%E5%91%8A%E6%9C%9F%E5%86%85%E4%B8%BB%E8%A6%81%E7%BB%8F%E8%90%A5%E6%83%85%E5%86%B5) This section provides a detailed analysis of the company's financial statement item changes, asset and liability status, and investment activities, including significant asset and equity sales - Operating revenue: **CNY 584 million**, a year-on-year decrease of **40.20%**, mainly due to the transfer of some subsidiaries and optimization of customer structure[93](index=93&type=chunk)[94](index=94&type=chunk) - Total profit: **CNY -51.93 million**, a year-on-year decrease of **495.76%**[93](index=93&type=chunk)[94](index=94&type=chunk) - R&D expenses: **CNY 24.53 million**, a year-on-year increase of **21.63%**, mainly due to increased expenses related to R&D projects[93](index=93&type=chunk)[94](index=94&type=chunk) - Net cash flow from operating activities: **CNY -79.17 million**, mainly due to decreased cash received from sales of goods and provision of services[93](index=93&type=chunk)[94](index=94&type=chunk) - Total assets: **CNY 2.20 billion**, a year-on-year decrease of **22.30%**, mainly due to subsidiary transfers[23](index=23&type=chunk)[96](index=96&type=chunk) - Net assets attributable to shareholders of the listed company: **CNY 877 million**, a year-on-year decrease of **6.17%**[23](index=23&type=chunk)[96](index=96&type=chunk) - Significant equity sale: In December **2024**, the company transferred **51%** equity of its controlling subsidiary Inner Mongolia Saily for **CNY 24.80 million**, with all transfer payments received[104](index=104&type=chunk) [(I) Analysis of Main Business](index=25&type=section&id=%28%E4%B8%80%29%20%E4%B8%BB%E8%90%A5%E4%B8%9A%E5%8A%A1%E5%88%86%E6%9E%90) This section provides an analysis of key financial statement item changes, explaining variations in operating revenue, costs, expenses, and cash flow Financial Statement Item Variation Analysis | Item | Current Period Amount (CNY) | Prior Year Period Amount (CNY) | Change (%) | Reason for Change | | :--- | :--- | :--- | :--- | :--- | | Operating Revenue | 583,500,840.55 | 975,687,565.49 | -40.20 | Transfer of some subsidiaries and customer structure optimization | | Operating Cost | 452,874,288.96 | 789,547,057.50 | -42.64 | Decrease in revenue | | Selling Expenses | 47,023,885.66 | 60,837,700.23 | -22.71 | Decrease in employee compensation and entertainment expenses | | R&D Expenses | 24,527,034.96 | 20,165,973.96 | 21.63 | Increase in expenses related to R&D projects | | Net Cash Flow from Operating Activities | -79,169,044.62 | -48,877,944.40 | N/A | Decrease in cash received from sales of goods and provision of services | | Investment Income | 9,736,549.95 | -1,810,379.62 | 637.82 | Investment income recognized from subsidiary transfer | | Credit Impairment Losses | -14,002,932.83 | 19,594,697.12 | -171.46 | Increase in impairment losses on accounts receivable | [(III) Analysis of Assets and Liabilities](index=26&type=section&id=%28%E4%B8%89%29%20%E8%B5%84%E4%BA%A7%E3%80%81%E8%B4%9F%E5%80%BA%E6%83%85%E5%86%B5%E5%88%86%E6%9E%90) This section analyzes period-end asset and liability changes, including cash, accounts receivable, and accounts payable, attributing changes to subsidiary transfers and collections Asset and Liability Changes | Item Name | Current Period-end Amount (CNY) | Prior Year-end Amount (CNY) | Change (%) | Reason for Change | | :--- | :--- | :--- | :--- | :--- | | Cash and Bank Balances | 122,324,295.57 | 209,435,589.90 | -41.59 | Mainly due to subsidiary transfers | | Accounts Receivable | 891,918,626.81 | 1,288,755,013.77 | -30.79 | Mainly due to subsidiary transfers and collections | | Accounts Payable | 312,200,873.12 | 730,412,691.86 | -57.26 | Mainly due to subsidiary transfers | | Total Assets | 2,199,028,725.29 | 2,830,070,456.98 | -22.30 | | | Net Assets Attributable to Shareholders of Listed Company | 876,660,040.59 | 934,292,086.63 | -6.17 | | - Overseas assets amounted to **CNY 98.63 million**, accounting for **4.49%** of total assets[98](index=98&type=chunk) [(IV) Investment Status Analysis](index=27&type=section&id=%28%E5%9B%9B%29%20%E6%8A%95%E8%B5%84%E7%8A%B6%E5%86%B5%E5%88%86%E6%9E%90) This section outlines the company's overall equity investment situation during the reporting period, with a 20.23% decrease year-on-year, and discloses financial assets measured at fair value - Investment amount during the reporting period: **CNY 8.99 million**, a year-on-year decrease of **20.23%**[100](index=100&type=chunk) Period-end Financial Assets Measured at Fair Value | Asset Category | Period-end Amount (CNY) | | :--- | :--- | | Accounts Receivable Financing | 2,760,544.35 | | Trading Financial Assets | 899,028.00 | | Other Equity Instrument Investments | 238,641,903.44 | | Total | 242,301,475.79 | [(V) Significant Asset and Equity Sales](index=29&type=section&id=%28%E4%BA%94%29%20%E9%87%8D%E5%A4%A7%E8%B5%84%E4%BA%A7%E5%92%8C%E8%82%A1%E6%9D%83%E5%87%BA%E5%94%AE) This section discloses the significant transfer of 51% equity in controlling subsidiary Inner Mongolia Saily in December 2024 for CNY 24.80 million, with all payments received - In December **2024**, the company transferred **51%** equity of Inner Mongolia Saily to Shanghai Jiayueheng Medical Equipment Co., Ltd. for **CNY 24.80 million**[104](index=104&type=chunk) - As of the report disclosure date, the company has received all equity transfer payments[104](index=104&type=chunk) [(VI) Analysis of Major Holding and Associate Companies](index=29&type=section&id=%28%E5%85%AD%29%20%E4%B8%BB%E8%A6%81%E6%8E%A7%E8%82%A1%E5%8F%82%E8%82%A1%E5%85%AC%E5%8F%B8%E5%88%86%E6%9E%90) This section details the operating performance of major subsidiaries and important associate companies, including financial data and specific updates on financing and litigation Operating Performance of Major Subsidiaries (Partial) | Company Name | Registered Capital (CNY) | Total Assets (CNY) | Net Assets (CNY) | Operating Revenue (CNY) | Net Profit (CNY) | | :--- | :--- | :--- | :--- | :--- | :--- | | Saily Bio | 500,000.00 | 133,564,882.91 | 72,423,374.14 | 13,358,551.73 | -2,851,346.73 | | Beijing Supply Chain | 10,000,000.00 | 216,089,458.58 | 45,390,858.95 | 190,946,869.53 | 7,789,236.78 | | Jining Kangzhiyi | 5,000,000.00 | 211,494,158.72 | 27,829,454.60 | 57,760,465.13 | 13,044,699.44 | Operating Performance of Important Associate Companies (Partial) | Company Name | Registered Capital (CNY) | Total Assets (CNY) | Net Assets (CNY) | Operating Revenue (CNY) | Net Profit (CNY) | | :--- | :--- | :--- | :--- | :--- | :--- | | Wuhan Huajiyuan Bio | 4,336,100.00 | 2,969,005.38 | -31,243,704.27 | 0.00 | -8,702,817.00 | | Sichuan Xiegung | 22,791,786.00 | 85,565,321.17 | -4,104,887.65 | 52,305,744.50 | -17,185,747.96 | | Wuhan Jindou Medical | 14,844,700.00 | 181,205,847.47 | 11,902,439.52 | 7,765,478.61 | -3,728,745.61 | - Sichuan Xiegung Biotechnology Co., Ltd. completed its latest round of financing, with a post-investment valuation of **CNY 800 million**[106](index=106&type=chunk) - In the Saiweihanpu loan dispute case, the company has applied for compulsory enforcement, but apart from the remaining frozen assets under preservation, there are no other bank deposits[107](index=107&type=chunk)[108](index=108&type=chunk) [V. Other Disclosure Matters](index=31&type=section&id=%E4%BA%94%E3%80%81%E5%85%B6%E4%BB%96%E6%8A%AB%E9%9C%B2%E4%BA%8B%E9%A1%B9) This section highlights potential risks including industry policy impacts, intensified market competition, internal control challenges, and increased accounts receivable and funding pressure - Industry policy impact risk: Deepening healthcare system reform, normalized policies like centralized procurement and medical insurance cost control, pose higher demands on the company's development[109](index=109&type=chunk)[110](index=110&type=chunk) - Intensified market competition risk: Industry development is mature, potential entrants are increasing, and the development of internet businesses intensifies market competition[111](index=111&type=chunk) - Internal control and operational management risks: Numerous subsidiaries with wide geographical distribution increase management complexity, and international development faces cross-border operational management risks[112](index=112&type=chunk) - Accounts receivable and funding pressure risks: Long collection cycles from medical institutions lead to high accounts receivable balances, posing bad debt risks and working capital occupation risks[113](index=113&type=chunk) [Section IV Corporate Governance, Environment, and Society](index=34&type=section&id=%E7%AC%AC%E5%9B%9B%E8%8A%82%20%E5%85%AC%E5%8F%B8%E6%B2%BB%E7%90%86%E3%80%81%E7%8E%AF%E5%A2%83%E5%92%8C%E7%A4%BE%E4%BC%9A) This section covers changes in directors, supervisors, and senior management, profit distribution plans, equity incentives, environmental information, and rural revitalization efforts [I. Changes in Directors, Supervisors, and Senior Management](index=34&type=section&id=%E4%B8%80%E3%80%81%E5%85%AC%E5%8F%B8%E8%91%A3%E4%BA%8B%E3%80%81%E7%9B%91%E4%BA%8B%E3%80%81%E9%AB%98%E7%BA%A7%E7%AE%A1%E7%90%86%E4%BA%BA%E5%91%98%E5%8F%98%E5%8A%A8%E6%83%85%E5%86%B5) There were no changes in the company's directors, supervisors, or senior management during the reporting period - No changes in the company's directors, supervisors, or senior management during the reporting period[116](index=116&type=chunk) [II. Profit Distribution or Capital Reserve to Share Capital Increase Plan](index=34&type=section&id=%E4%BA%8C%E3%80%81%E5%88%A9%E6%B6%A6%E5%88%86%E9%85%8D%E6%88%96%E8%B5%84%E6%9C%AC%E5%85%AC%E7%A7%AF%E9%87%91%E8%BD%AC%E5%A2%9E%E9%A2%84%E6%A1%88) There is no profit distribution or capital reserve to share capital increase plan for the reporting period - No profit distribution or capital reserve to share capital increase plan for the reporting period[116](index=116&type=chunk) [III. Status and Impact of Company Equity Incentive Plans, Employee Stock Ownership Plans, or Other Employee Incentive Measures](index=34&type=section&id=%E4%B8%89%E3%80%81%E5%85%AC%E5%8F%B8%E8%82%A1%E6%9D%83%E6%BF%80%E5%8A%B1%E8%AE%A1%E5%88%92%E3%80%81%E5%91%98%E5%B7%A5%E6%8C%81%E8%82%A1%E8%AE%A1%E5%88%92%E6%88%96%E5%85%B6%E4%BB%96%E5%91%98%E5%B7%A5%E6%BF%80%E5%8A%B1%E6%8E%AA%E6%96%BD%E7%9A%84%E6%83%85%E5%86%B5%E5%8F%8A%E5%85%B6%E5%BD%B1%E5%93%8D) There were no equity incentive plans, employee stock ownership plans, or other employee incentive measures during the reporting period - No equity incentive plans, employee stock ownership plans, or other employee incentive measures during the reporting period[117](index=117&type=chunk) [IV. Environmental Information of Listed Companies and Their Major Subsidiaries Included in the List of Enterprises Required to Disclose Environmental Information by Law](index=34&type=section&id=%E5%9B%9B%E3%80%81%E7%BA%B3%E5%85%A5%E7%8E%AF%E5%A2%83%E4%BF%A1%E6%81%AF%E4%BE%9D%E6%B3%95%E6%8A%AB%E9%9C%B2%E4%BC%81%E4%B8%9A%E5%90%8D%E5%8D%95%E7%9A%84%E4%B8%8A%E5%B8%82%E5%85%AC%E5%8F%B8%E5%8F%8A%E5%85%B6%E4%B8%BB%E8%A6%81%E5%AD%90%E5%85%AC%E5%8F%B8%E7%9A%84%E7%8E%AF%E5%A2%83%E4%BF%A1%E6%81%AF%E6%83%85%E5%86%B5) The company was not included in the list of enterprises required to disclose environmental information by law during the reporting period - The company was not included in the list of enterprises required to disclose environmental information by law during the reporting period[117](index=117&type=chunk) [V. Specific Situation of Consolidating and Expanding Poverty Alleviation Achievements, Rural Revitalization, and Other Work](index=34&type=section&id=%E4%BA%94%E3%80%81%E5%B7%A9%E5%9B%BA%E6%8B%93%E5%B1%95%E8%84%B1%E8%B4%AB%E6%94%BB%E5%9D%9A%E6%88%90%E6%9E%9C%E3%80%81%E4%B9%A1%E6%9D%91%E6%8C%AF%E5%85%B4%E7%AD%89%E5%B7%A5%E4%BD%9C%E5%85%B7%E4%BD%93%E6%83%85%E5%86%B5) There were no specific activities related to consolidating poverty alleviation achievements or rural revitalization during the reporting period - No specific activities related to consolidating poverty alleviation achievements or rural revitalization during the reporting period[117](index=117&type=chunk) [Section V Significant Matters](index=35&type=section&id=%E7%AC%AC%E4%BA%94%E8%8A%82%20%E9%87%8D%E8%A6%81%E4%BA%8B%E9%A1%B9) This section details significant events including commitment fulfillment, related party transactions, legal proceedings, regulatory penalties, and fundraising activities [I. Fulfillment of Commitments](index=35&type=section&id=%E4%B8%80%E3%80%81%E6%89%BF%E8%AF%BA%E4%BA%8B%E9%A1%B9%E5%B1%A5%E8%A1%8C%E6%83%85%E5%86%B5) This section discloses the fulfillment of commitments regarding financing cooperation and voting rights entrustment between controlling shareholder Saihai Technology and Hubei Changjiang Jingxuan Jilun No. 1 Ecological Investment Partnership - Controlling shareholder Saihai Technology engaged in financing cooperation with Hubei Changjiang Jingxuan Jilun No. 1 Ecological Investment Partnership (Limited Partnership), which irrevocably entrusted the voting rights of its **1,773,000** shares to Saihai Technology[119](index=119&type=chunk) - The commitment period is from July 7, **2023**, to July 6, **2028**, and was strictly fulfilled during the reporting period[119](index=119&type=chunk) [II. Non-Operating Funds Occupied by Controlling Shareholder and Other Related Parties During the Reporting Period](index=35&type=section&id=%E4%BA%8C%E3%80%81%E6%8A%A5%E5%91%8A%E6%9C%9F%E5%86%85%E6%8E%A7%E8%82%A1%E8%82%A1%E4%B8%9C%E5%8F%8A%E5%85%B6%E4%BB%96%E5%85%B3%E8%81%94%E6%96%B9%E9%9D%9E%E7%BB%8F%E8%90%A5%E6%80%A7%E5%8D%A0%E7%94%A8%E8%B5%84%E9%87%91%E6%83%85%E5%86%B5) There was no non-operating occupation of funds by controlling shareholders or other related parties during the reporting period - No non-operating occupation of funds by controlling shareholders or other related parties during the reporting period[120](index=120&type=chunk) [III. Irregular Guarantees](index=35&type=section&id=%E4%B8%89%E3%80%81%E8%BF%9D%E8%A7%84%E6%8B%85%E4%BF%9D%E6%83%85%E5%86%B5) There were no external guarantees provided in violation of decision-making procedures during the reporting period - No external guarantees provided in violation of decision-making procedures during the reporting period[120](index=120&type=chunk) [IV. Semi-Annual Report Audit Status](index=36&type=section&id=%E5%9B%9B%E3%80%81%E5%8D%8A%E5%B9%B4%E6%8A%A5%E5%AE%A1%E8%AE%A1%E6%83%85%E5%86%B5) This semi-annual report has not been audited - This semi-annual report is unaudited[5](index=5&type=chunk) [V. Changes and Handling of Matters Related to Non-Standard Audit Opinions in the Previous Annual Report](index=36&type=section&id=%E4%BA%94%E3%80%81%E4%B8%8A%E5%B9%B4%E5%B9%B4%E5%BA%A6%E6%8A%A5%E5%91%8A%E9%9D%9E%E6%A0%87%E5%87%86%E5%AE%A1%E8%AE%A1%E6%84%8F%E8%A7%81%E6%B6%89%E5%8F%8A%E4%BA%8B%E9%A1%B9%E7%9A%84%E5%8F%98%E5%8C%96%E5%8F%8A%E5%A4%84%E7%90%86%E6%83%85%E5%86%B5) There were no changes or handling of matters related to non-standard audit opinions from the previous annual report during the reporting period - No changes or handling of matters related to non-standard audit opinions from the previous annual report during the reporting period[121](index=121&type=chunk) [VI. Bankruptcy and Reorganization Matters](index=36&type=section&id=%E5%85%AD%E3%80%81%E7%A0%B4%E4%BA%A7%E9%87%8D%E6%95%B4%E7%9B%B8%E5%85%B3%E4%BA%8B%E9%A1%B9) There were no bankruptcy and reorganization matters during the reporting period - No bankruptcy and reorganization matters during the reporting period[121](index=121&type=chunk) [VII. Significant Litigation and Arbitration Matters](index=36&type=section&id=%E4%B8%83%E3%80%81%E9%87%8D%E5%A4%A7%E8%AF%89%E8%AE%BC%E3%80%81%E4%BB%B2%E8%A3%81%E4%BA%8B%E9%A1%B9) This section discloses significant litigation and arbitration cases involving the company and its subsidiaries, including ongoing, withdrawn, and settled cases - Three cases, including Hunan Jieying Biotechnology Co., Ltd. vs. Wuhan Kangshengda Medical Laboratory Co., Ltd. regarding a deposit contract dispute, are still awaiting judgment[121](index=121&type=chunk) - During the reporting period, three cases involving Inner Mongolia Saily Medical Technology Co., Ltd. concerning company license return disputes and changes in company registration were withdrawn[123](index=123&type=chunk)[124](index=124&type=chunk) - Shandong Sichuang Medical Equipment Co., Ltd. vs. Shandong Runcheng Medical Technology Co., Ltd. regarding a sales contract dispute has been judged and fulfilled, with a claim amount of **CNY 2.54 million**[124](index=124&type=chunk) - Saily Medical vs. Qingyuan Ruitong Medical Equipment Co., Ltd. regarding a loan dispute has been judged, with a claim amount of **CNY 18.79 million**, currently under enforcement[125](index=125&type=chunk) [VIII. Listed Company and Its Directors, Supervisors, Senior Management, Controlling Shareholder, Actual Controller Suspected of Violations, Penalties, and Rectification](index=38&type=section&id=%E5%85%AB%E3%80%81%E4%B8%8A%E5%B8%82%E5%85%AC%E5%8F%B8%E5%8F%8A%E5%85%B6%E8%91%A3%E4%BA%8B%E3%80%81%E7%9B%91%E4%BA%8B%E3%80%81%E9%AB%98%E7%BA%A7%E7%AE%A1%E7%90%86%E4%BA%BA%E5%91%98%E3%80%81%E6%8E%A7%E8%82%A1%E8%82%A1%E4%B8%9C%E3%80%81%E5%AE%9E%E9%99%85%E6%8E%A7%E5%88%B6%E4%BA%BA%E6%B6%89%E5%AB%8C%E8%BF%9D%E6%B3%95%E8%BF%9D%E8%A7%84%E3%80%81%E5%8F%97%E5%88%B0%E5%A4%84%E7%BD%9A%E5%8F%8A%E6%95%B4%E6%94%B9%E6%83%85%E5%86%B5) This section discloses regulatory penalties and rectification efforts for the company and related parties due to unreturned raised funds, information disclosure violations, related party transaction irregularities, and non-operating fund occupation - On April 1, **2025**, the company received a public reprimand from the Shanghai Stock Exchange and an order for rectification from the Hubei Securities Regulatory Bureau for not returning raised funds on time; the company has since returned all overdue raised funds[126](index=126&type=chunk) - On April 1, **2025**, the company was investigated by the China Securities Regulatory Commission for alleged information disclosure violations and received an administrative penalty decision on April 23, resulting in a **CNY 6 million** fine[127](index=127&type=chunk) - Then-Chairman Wen Wei, then-General Manager Wang Zheng, then-CFO Shen Yan, and other responsible persons also received corresponding penalties and regulatory warnings[127](index=127&type=chunk)[128](index=128&type=chunk) [IX. Explanation of the Integrity Status of the Company, Its Controlling Shareholder, and Actual Controller During the Reporting Period](index=39&type=section&id=%E4%B9%9D%E3%80%81%E6%8A%A5%E5%91%8A%E6%9C%9F%E5%86%85%E5%85%AC%E5%8F%B8%E5%8F%8A%E5%85%B6%E6%8E%A7%E8%82%A1%E8%82%A1%E4%B8%9C%E3%80%81%E5%AE%9E%E9%99%85%E6%8E%A7%E5%88%B6%E4%BA%BA%E8%AF%9A%E4%BF%A1%E7%8A%B6%E5%86%B5%E7%9A%84%E8%AF%B4%E6%98%8E) There is no explanation of the integrity status of the company, its controlling shareholder, or actual controller during the reporting period - No explanation of the integrity status of the company, its controlling shareholder, or actual controller during the reporting period[129](index=129&type=chunk) [X. Significant Related Party Transactions](index=39&type=section&id=%E5%8D%81%E3%80%81%E9%87%8D%E5%A4%A7%E5%85%B3%E8%81%94%E4%BA%A4%E6%98%93) There were no significant related party transactions during the reporting period - No significant related party transactions during the reporting period[129](index=129&type=chunk)[130](index=130&type=chunk) [XI. Significant Contracts and Their Fulfillment](index=40&type=section&id=%E5%8D%81%E4%B8%80%E3%80%81%E9%87%8D%E5%A4%A7%E5%90%88%E5%90%8C%E5%8F%8A%E5%85%B6%E5%B1%A5%E8%A1%8C%E6%83%85%E5%86%B5) This section discloses significant guarantees provided by the company for its subsidiaries, with a total outstanding guarantee balance of CNY 0 at the end of the reporting period - Total guarantee amount for subsidiaries during the reporting period: **CNY 13.80 million**[132](index=132&type=chunk) - Total outstanding guarantee balance for subsidiaries at period-end: **CNY 0.00**[132](index=132&type=chunk) - Ratio of total guarantees to company net assets: **0.00%**[132](index=132&type=chunk) [XII. Explanation of Progress in Use of Raised Funds](index=42&type=section&id=%E5%8D%81%E4%BA%8C%E3%80%81%E5%8B%9F%E9%9B%86%E8%B5%84%E9%87%91%E4%BD%BF%E7%94%A8%E8%BF%9B%E5%B1%95%E8%AF%B4%E6%98%8E) This section details the overall use of raised funds, investment project specifics, changes or termination of projects, and temporary use of idle funds for working capital Overall Use of Raised Funds | Source of Raised Funds | Total Raised Funds (CNY) | Cumulative Investment Amount as of Period-end (CNY) | Cumulative Investment Progress (%) | | :--- | :--- | :--- | :--- | | Targeted Issuance of Shares (June 2018) | 625,959,956.79 | 607,501,224.50 | 99.98 | | Convertible Corporate Bonds (August 2020) | 543,310,000.00 | 202,784,654.49 | 38.07 | | Total | 1,169,269,956.79 | 810,285,878.99 | / | - Change or termination of fundraising projects: The "Expansion of Medical Testing Centralized Marketing and Service Business Scale Project" was canceled on June 5, **2025**; prior to termination, the total raised funds invested in the project were **CNY 388.09 million**, with **CNY 219.25 million** already invested; after termination, the amount of raised funds used for working capital was **CNY 172.54 million**[141](index=141&type=chunk)[142](index=142&type=chunk) - Use of idle raised funds to supplement working capital: Approved to use up to **CNY 325 million** of idle raised funds to temporarily supplement working capital for a period not exceeding **12 months**, which has not yet expired as of the report disclosure date[143](index=143&type=chunk) [XIII. Explanation of Other Significant Matters](index=48&type=section&id=%E5%8D%81%E4%B8%89%E3%80%81%E5%85%B6%E4%BB%96%E9%87%8D%E5%A4%A7%E4%BA%8B%E9%A1%B9%E7%9A%84%E8%AF%B4%E6%98%8E) There are no other significant matters to explain during the reporting period - No other significant matters to explain during the reporting period[144](index=144&type=chunk) [Section VI Share Changes and Shareholder Information](index=49&type=section&id=%E7%AC%AC%E5%85%AD%E8%8A%82%20%E8%82%A1%E4%BB%BD%E5%8F%98%E5%8A%A8%E5%8F%8A%E8%82%A1%E4%B8%9C%E6%83%85%E5%86%B5) This section details changes in share capital, shareholder structure, and the status of directors, supervisors, and senior management [I. Share Capital Changes](index=49&type=section&id=%E4%B8%80%E3%80%81%E8%82%A1%E6%9C%AC%E5%8F%98%E5%8A%A8%E6%83%85%E5%86%B5) This section discloses share capital changes during the reporting period, primarily due to convertible bond conversion, and its impact on EPS and net assets per share - During the reporting period (January 1, **2025**, to June 30, **2025**), the company's total share capital increased by **29,821** shares due to convertible bond conversion[147](index=147&type=chunk) - Total shares at period-end: **191,018,075** shares[146](index=146&type=chunk) - After the reporting period (July 1, **2025**, to August 20, **2025**), convertible bonds were cumulatively converted into **19,121,171** shares, increasing the company's total share capital to **210,139,246** shares[149](index=149&type=chunk) - After conversion, basic earnings per share were **CNY -0.2869/share**, and net assets per share were **CNY 4.5655/share**[149](index=149&type=chunk) [II. Shareholder Information](index=50&type=section&id=%E4%BA%8C%E3%80%81%E8%82%A1%E4%B8%9C%E6%83%85%E5%86%B5) This section discloses the total number of ordinary shareholders, top ten shareholders, and top ten unrestricted shareholders at period-end, including shareholdings, percentages, and pledge status - Total number of ordinary shareholders at period-end: **45,698** households[150](index=150&type=chunk) Top Ten Shareholders' Shareholding (Partial) | Shareholder Name | Period-end Shareholding (shares) | Percentage (%) | Pledged Quantity (shares) | Shareholder Nature | | :--- | :--- | :--- | :--- | :--- | | Saihai (Shanghai) Health Technology Co., Ltd. | 21,642,540 | 11.33 | 15,800,000 | Domestic Non-State-Owned Legal Person | | Shanghai Angze Private Equity Fund Management Co., Ltd. - Angze Taiying No. 6 Private Securities Investment Fund | 12,100,399 | 6.33 | 0 | Other | | Wen Wei | 9,634,208 | 5.04 | 9,150,000 | Domestic Natural Person | - Controlling shareholder Saihai Technology transferred shares to Hubei Changjiang Jingxuan Jilun No. 1 Ecological Investment Partnership (Limited Partnership) via block trade, and Jilun No. 1 irrevocably entrusted its voting rights to Saihai Technology[154](index=154&type=chunk) [III. Information on Directors, Supervisors, and Senior Management](index=52&type=section&id=%E4%B8%89%E3%80%81%E8%91%A3%E4%BA%8B%E3%80%81%E7%9B%91%E4%BA%8B%E5%92%8C%E9%AB%98%E7%BA%A7%E7%AE%A1%E7%90%86%E4%BA%BA%E5%91%98%E6%83%85%E5%86%B5) There were no changes in shareholdings or equity incentives for the company's directors, supervisors, and senior management during the reporting period - No changes in shareholdings or equity incentives for the company's directors, supervisors, and senior management during the reporting period[155](index=155&type=chunk) [IV. Changes in Controlling Shareholder or Actual Controller](index=52&type=section&id=%E5%9B%9B%E3%80%81%E6%8E%A7%E8%82%A1%E8%82%A1%E4%B8%9C%E6%88%96%E5%AE%9E%E9%99%85%E6%8E%A7%E5%88%B6%E4%BA%BA%E5%8F%98%E6%9B%B4%E6%83%85%E5%86%B5) There were no changes in the company's controlling shareholder or actual controller during the reporting period - No changes in the company's controlling shareholder or actual controller during the reporting period[155](index=155&type=chunk) [V. Preferred Share Information](index=52&type=section&id=%E4%BA%94%E3%80%81%E4%BC%98%E5%85%88%E8%82%A1%E7%9B%B8%E5%85%B3%E6%83%85%E5%86%B5) There is no preferred share information for the company during the reporting period - No preferred share information for the company during the reporting period[155](index=155&type=chunk) [Section VII Bond-Related Information](index=53&type=section&id=%E7%AC%AC%E4%B8%83%E8%8A%82%20%E5%80%BA%E5%88%B8%E7%9B%B8%E5%85%B3%E6%83%85%E5%86%B5) This section provides details on the company's bond instruments, specifically focusing on the convertible corporate bonds [I. Corporate Bonds (Including Enterprise Bonds) and Non-Financial Enterprise Debt Financing Instruments](index=53&type=section&id=%E4%B8%80%E3%80%81%E5%85%AC%E5%8F%B8%E5%80%BA%E5%88%B8%EF%BC%88%E5%90%AB%E4%BC%81%E4%B8%9A%E5%80%BA%E5%88%B8%EF%BC%89%E5%92%8C%E9%9D%9E%E9%87%91%E8%9E%8D%E4%BC%81%E4%B8%9A%E5%80%BA%E5%8A%A1%E8%9E%8D%E8%B5%84%E5%B7%A5%E5%85%B7) There were no corporate bonds (including enterprise bonds) or non-financial enterprise debt financing instruments during the reporting period - No corporate bonds (including enterprise bonds) or non-financial enterprise debt financing instruments during the reporting period[157](index=157&type=chunk) [II. Convertible Corporate Bonds](index=53&type=section&id=%E4%BA%8C%E3%80%81%E5%8F%AF%E8%BD%AC%E6%8D%A2%E5%85%AC%E5%8F%B8%E5%80%BA%E6%83%85%E5%86%B5) This section details the issuance, holder information, changes, cumulative conversion, price adjustments, debt status, credit rating, and future repayment plans for the company's convertible corporate bonds - Issuance: On August 21, **2020**, **CNY 543.31 million** convertible corporate bonds, named "Saily Convertible Bonds" (code "113601"), were publicly issued[157](index=157&type=chunk) - Number of convertible bondholders at period-end: **8,500** households[158](index=158&type=chunk) Convertible Bond Changes During the Reporting Period | Convertible Corporate Bond | Before This Change (CNY) | Increase/Decrease in This Change (CNY) | After This Change (CNY) | | :--- | :--- | :--- | :--- | | Saily Convertible Bonds | 418,169,000 | 358,000 | 417,811,000 | - Cumulative conversion: Conversion amount during the reporting period was **CNY 0.36 million**, with **29,821** shares converted; cumulative converted shares totaled **114,799**, accounting for **0.0560%** of the company's total shares issued before conversion[161](index=161&type=chunk) - Historical adjustments to conversion price: Adjusted to **CNY 13.71/share** in September **2024**, **CNY 12.71/share** in October **2024**, **CNY 12.50/share** in November **2024**, and **CNY 12.00/share** in February **2025**[163](index=163&type=chunk)[164](index=164&type=chunk) - Debt situation: As of the end of the reporting period, the company's asset-liability ratio was **61.42%**[165](index=165&type=chunk) - Credit rating: China Chengxin International Credit Rating Co., Ltd. rated the company's main credit rating as "BB+" with a "stable" outlook, and "Saily Convertible Bonds" credit rating as "BB+"[165](index=165&type=chunk) - Post-reporting period conversion: From July 1 to August 20, **2025**, cumulative convertible bond conversion amounted to **CNY 229.47 million**, with an unconverted balance of **CNY 188.35 million**, accounting for **34.67%** of the total issuance[166](index=166&type=chunk) [Section VIII Financial Report](index=56&type=section&id=%E7%AC%AC%E5%85%AB%E8%8A%82%20%E8%B4%A2%E5%8A%A1%E6%8A%A5%E5%91%8A) This section contains the company's unaudited financial statements, including balance sheets, income statements, cash flow statements, and statements of changes in equity [I. Audit Report](index=56&type=section&id=%E4%B8%80%E3%80%81%E5%AE%A1%E8%AE%A1%E6%8A%A5%E5%91%8A) This semi-annual report has not been audited - This semi-annual report is unaudited[5](index=5&type=chunk) [II. Financial Statements](index=56&type=section&id=%E4%BA%8C%E3%80%81%E8%B4%A2%E5%8A%A1%E6%8A%A5%E8%A1%A8) This section includes the company's consolidated and parent company balance sheets, income statements, cash flow statements, and statements of changes in owners' equity [Consolidated Balance Sheet](index=56&type=section&id=%E5%90%88%E5%B9%B6%E8%B5%84%E4%BA%A7%E8%B4%9F%E5%80%BA%E8%A1%A8) As of June 30, 2025, the company's consolidated total assets were CNY 2.20 billion, total liabilities CNY 1.35 billion, and total owners' equity CNY 0.85 billion - Total assets: **CNY 2.20 billion**[171](index=171&type=chunk) - Total liabilities: **CNY 1.35 billion**[171](index=171&type=chunk) - Total owners' equity: **CNY 848.47 million**[171](index=171&type=chunk) [Parent Company Balance Sheet](index=58&type=section&id=%E6%AF%8D%E5%85%AC%E5%8F%B8%E8%B5%84%E4%BA%A7%E8%B4%9F%E5%80%BA%E8%A1%A8) As of June 30, 2025, the parent company's total assets were CNY 2.00 billion, total liabilities CNY 0.87 billion, and total owners' equity CNY 1.13 billion - Total assets: **CNY 2.00 billion**[174](index=174&type=chunk) - Total liabilities: **CNY 868.09 million**[174](index=174&type=chunk) - Total owners' equity: **CNY 1.13 billion**[174](index=174&type=chunk) [Consolidated Income Statement](index=60&type=section&id=%E5%90%88%E5%B9%B6%E5%88%A9%E6%B6%A6%E8%A1%A8) For Jan-Jun 2025, the company's consolidated total operating revenue was CNY 0.58 billion, total operating costs CNY 0.63 billion, net loss CNY 51.55 million, and net loss attributable to parent company shareholders CNY 56.12 million - Total operating revenue: **CNY 583.50 million**[176](index=176&type=chunk) - Total operating costs: **CNY 631.91 million**[176](index=176&type=chunk) - Net profit: **CNY -51.55 million**[177](index=177&type=chunk) - Net profit attributable to parent company shareholders: **CNY -56.12 million**[177](index=177&type=chunk) [Parent Company Income Statement](index=62&type=section&id=%E6%AF%8D%E5%85%AC%E5%8F%B8%E5%88%A9%E6%B6%A6%E8%A1%A8) For Jan-Jun 2025, the parent company's operating revenue was CNY 0.11 billion, and net profit was CNY 17.75 million - Operating revenue: **CNY 111.70 million**[180](index=180&type=chunk) - Net profit: **CNY 17.75 million**[181](index=181&type=chunk) [Consolidated Cash Flow Statement](index=63&type=section&id=%E5%90%88%E5%B9%B6%E7%8E%B0%E9%87%91%E6%B5%81%E9%87%8F%E8%A1%A8) For Jan-Jun 2025, net cash flow from operating activities was CNY -79.17 million, from investing activities CNY 39.97 million, and from financing activities CNY -47.21 million - Net cash flow from operating activities: **CNY -79.17 million**[184](index=184&type=chunk) - Net cash flow from investing activities: **CNY 39.97 million**[184](index=184&type=chunk) - Net cash flow from financing activities: **CNY -47.21 million**[185](index=185&type=chunk) [Parent Company Cash Flow Statement](index=65&type=section&id=%E6%AF%8D%E5%85%AC%E5%8F%B8%E7%8E%B0%E9%87%91%E6%B5%81%E9%87%8F%E8%A1%A8) For Jan-Jun 2025, net cash flow from operating activities was CNY 0.70 million, from investing activities CNY 103.52 million, and from financing activities CNY -95.39 million - Net cash flow from operating activities: **CNY 0.70 million**[187](index=187&type=chunk) - Net cash flow from investing activities: **CNY 103.52 million**[188](index=188&type=chunk) - Net cash flow from financing activities: **CNY -95.39 million**[188](index=188&type=chunk) [Consolidated Statement of Changes in Owners' Equity](index=67&type=section&id=%E5%90%88%E5%B9%B6%E6%89%80%E6%9C%89%E8%80%85%E6%9D%83%E7%9B%8A%E5%8F%98%E5%8A%A8%E8%A1%A8) For Jan-Jun 2025, consolidated owners' equity decreased by CNY 113.58 million, mainly due to net loss and changes in minority interests - Amount of increase/decrease for the current period (decrease): **CNY -113.58 million**[190](index=190&type=chunk) - Total owners' equity at period-end: **CNY 848.47 million**[191](index=191&type=chunk) [Parent Company Statement of Changes in Owners' Equity](index=75&type=section&id=%E6%AF%8D%E5%85%AC%E5%8F%B8%E6%89%80%E6%9C%89%E8%80%85%E6%9D%83%E7%9B%8A%E5%8F%98%E5%8A%A8%E8%A1%A8) For Jan-Jun 2025, parent company owners' equity increased by CNY 17.22 million, primarily due to net profit - Amount of increase/decrease for the current period (increase): **CNY 17.22 million**[201](index=201&type=chunk) - Total owners' equity at period-end: **CNY 1.13 billion**[202](index=202&type=chunk) [III. Company Basic Information](index=79&type=section&id=%E4%B8%89%E3%80%81%E5%85%AC%E5%8F%B8%E5%9F%BA%E6%9C%AC%E6%83%85%E5%86%B5) This section details Saily Medical Technology Group Co., Ltd.'s history, registration, business scope, and number of consolidated subsidiaries - The company's predecessor was Wuhan Saily Biotechnology Co., Ltd., established on February 23, **2004**[204](index=204&type=chunk) - The company was wholly converted into a joint-stock company on July 6, **2012**[209](index=209&type=chunk) - Main business scope: Centralized operation services for medical testing (IVD collectivization), collaborative construction of regional testing centers, centralized operation services for medical consumables (SPD business), and pure sales business[218](index=218&type=chunk) - As of June 30, **2025**, the Group included **42** second-tier subsidiaries in its consolidated scope[218](index=218&type=chunk) [IV. Basis of Preparation of Financial Statements](index=83&type=section&id=%E5%9B%9B%E3%80%81%E8%B4%A2%E5%8A%A1%E6%8A%A5%E8%A1%A8%E7%9A%84%E7%BC%96%E5%88%B6%E5%9F%BA%E7%A1%80) This section states that the financial statements are prepared on a going concern basis, adhering to accounting standards, and using accrual basis and historical cost - Financial statements are prepared on a going concern basis[219](index=219&type=chunk) - Adhering to enterprise accounting standards, based on the accrual basis, and measured at historical cost except for financial instruments[220](index=220&type=chunk) [V. Significant Accounting Policies and Accounting Estimates](index=83&type=section&id=%E4%BA%94%E3%80%81%E9%87%8D%E8%A6%81%E4%BC%9A%E8%AE%A1%E6%94%BF%E7%AD%96%E5%8F%8A%E4%BC%9A%E8%AE%A1%E4%BC%B0%E8%AE%A1) This section lists the company's specific accounting policies and estimates for various financial items, including revenue recognition, financial instruments, inventory, and R&D expenses - The company has formulated specific accounting policies and estimates for revenue recognition, research and development expenditures, etc., based on its actual production and operation characteristics[221](index=221&type=chunk) - Materiality threshold: Single item amount accounts for more than **1%** of the corresponding receivables and exceeds **CNY 5 million**[226](index=226&type=chunk) - Financial assets are classified into three categories: measured at amortized cost, measured at fair value with changes recognized in other comprehensive income, and measured at fair value with changes recognized in current profit or loss[250](index=250&type=chunk) - Inventories are valued using the weighted average method upon issuance, and measured at the lower of cost and net realizable value at period-end[272](index=272&type=chunk)[274](index=274&type=chunk) - R&D expenditures are divided into research and development phases; research phase expenditures are recognized in current profit or loss, while development phase expenditures are recognized as intangible assets when conditions are met[304](index=304&type=chunk)[305](index=305&type=chunk) - Revenue recognition: Revenue is recognized when the customer obtains control of the related goods, considering factors such as variable consideration and significant financing components[328](index=328&type=chunk) - Government grants: Asset-related grants are recognized as deferred income, while income-related grants are recognized as deferred income or current profit or loss depending on the compensation object[337](index=337&type=chunk) - Significant accounting judgments and estimates include revenue recognition, leases, impairment of financial assets, inventory write-downs, impairment of long-term assets, depreciation and amortization, deferred tax assets, and income tax[355](index=355&type=chunk)[356](index=356&type=chunk)[360](index=360&type=chunk)[361](index=361&type=chunk)[362](index=362&type=chunk)[363](index=363&type=chunk)[364](index=364&type=chunk)[365](index=365&type=chunk)[366](index=366&type=chunk) [VI. Taxation](index=118&type=section&id=%E5%85%AD%E3%80%81%E7%A8%8E%E9%A1%B9) This section lists the company's main tax categories and rates, including VAT, urban maintenance and construction tax, and corporate income tax, noting preferential policies for subsidiaries - Main tax categories: Value-added tax (**13%**, **9%**, **6%**, **3%**), urban maintenance and construction tax (**7%**), education surcharge (**3%**), local education surcharge (**2%**), corporate income tax[368](index=368&type=chunk) - Subsidiaries Wuhan Saily Biotechnology Co., Ltd., Beijing Jingyang Tengwei Technology Development Co., Ltd., and Saily Medical Supply Chain Management (Beijing) Co., Ltd. enjoy high-tech enterprise income tax preferential policies, with a tax rate of **15%**[369](index=369&type=chunk)[370](index=370&type=chunk) - Subsidiaries Hebei Saily Medical Technology Co., Ltd. and Wuhan Ruichu Medical Technology Co., Ltd. enjoy small and micro-enterprise income tax preferential policies[371](index=371&type=chunk)[372](index=372&type=chunk) [VII. Notes to Consolidated Financial Statement Items](index=119&type=section&id=%E4%B8%83%E3%80%81%E5%90%88%E5%B9%B6%E8%B4%A2%E5%8A%A1%E6%8A%A5%E8%A1%A8%E9%A1%B9%E7%9B%AE%E6%B3%A8%E9%87%8A) This section provides detailed notes and explanations for various consolidated financial statement items, including period-end balances, beginning balances, changes, and reasons for changes - Cash and bank balances at period-end were **CNY 122 million**, a **41.59%** decrease from the beginning of the period, mainly due to subsidiary transfers[374](index=374&type=chunk) - Accounts receivable at period-end were **CNY 892 million**, a **30.79%** decrease from the beginning of the period, mainly due to subsidiary transfers and collections[387](index=387&type=chunk)[390](index=390&type=chunk) - Operating revenue was **CNY 584 million**, and operating costs were **CNY 453 million**, representing year-on-year decreases of **40.20%** and **42.64%**, respectively[531](index=531&type=chunk) - R&D expenses were **CNY 24.53 million**, a year-on-year increase of **21.63%**[538](index=538&type=chunk) [VIII. Research and Development Expenses](index=179&type=section&id=%E5%85%AB%E3%80%81%E7%A0%94%E5%8F%91%E6%94%AF%E5%87%BA) This section lists the composition of the company's R&D expenses for the current period, totaling CNY 24.53 million, all expensed, primarily for employee compensation and materials - Total R&D e

| 证券代码：603716 | 证券简称：塞力医疗 | 公告编号：2025-074 | | --- | --- | --- | | 债券代码：113601 | 债券简称：塞力转债 | | 塞力斯医疗科技集团股份有限公司 关于 2025 年半年度募集资金存放与实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据中国证券监督管理委员会发布的《上市公司募集资金监管规则》和上海 证券交易所发布的《上海证券交易所上市公司自律监管指引第1号——规范运作》 等有关规定，塞力斯医疗科技集团股份有限公司（以下简称"公司"或"塞力医 疗"）就2025年半年度募集资金存放与实际使用情况报告如下： 一、募集资金基本情况 （一）2018 年非公开发行 A 股股票募集资金 1、实际募集资金金额、资金到位时间 经中国证券监督管理委员会核发的《关于核准武汉塞力斯医疗科技股份有限 公司非公开发行股票的批复》（证监许可[2017]2322 号）核准，公司于 2018 年 6 月 5 日非公开发行 A 股股票 26,853,709 股，每股 ...

| 证券代码：603716 | 证券简称：塞力医疗 | 公告编号：2025-073 | | --- | --- | --- | | 债券代码：113601 | 债券简称：塞力转债 | | 本次会议审议并通过如下议案： 塞力斯医疗科技集团股份有限公司（以下简称"公司"）2025 年 8 月 17 日 以邮件方式发送第五届监事会第九次会议通知，会议于 2025 年 8 月 27 日在公司 A 栋 C 会议室以现场和通讯相结合的方式召开。本次会议应出席监事 3 人，实际 出席监事 3 人，会议由监事会主席陈德先生主持。会议的通知、召集、召开、表 决程序符合《公司法》及《公司章程》的相关规定。 二、监事会会议审议情况 （一）审议通过《关于公司 2025 年半年度报告及其摘要的议案》 一、监事会会议召开情况 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 塞力斯医疗科技集团股份有限公司 第五届监事会第九次会议决议公告 （二）审议通过《关于公司 2025 年半年度募集资金存放与实际使用情况的 专项报告的议案》 监事会认为： ...

塞力斯医疗科技集团股份有限公司 董事、高级管理人员所持公司股份及其变动管理规则 （2025 年 8 月） 第一章 总则 第一条 为加强塞力斯医疗科技集团股份有限公司（以下简称"公司"或"本 公司"）董事、高级管理人员所持公司股份及其变动的管理，进一步明确管理程 序，根据《中华人民共和国公司法》《中华人民共和国证券法》《上海证券交易所 股票上市规则》《上市公司董事和高级管理人员所持本公司股份及其变动管理规 则》《上市公司信息披露管理办法》《上海证券交易所上市公司自律监管指引第 8 号——股份变动管理》《上海证券交易所上市公司自律监管指引第 15 号——股东 及董事、高级管理人员减持股份》等法律、法规、规范性文件及《塞力斯医疗科 技集团股份有限公司章程》（以下简称"《公司章程》"）的规定，制定本规则。 第二条 本规则适用于公司的董事、高级管理人员所持公司股份及其变动的 管理。 第三条 董事、高级管理人员所持公司股份，是指登记在其名下和利用他人 账户持有的本公司股份；董事、高级管理人员从事融资融券交易的，其所持有的 本公司股份还包括记载在其信用账户内的本公司股份。 塞力斯医疗科技集团股份有限公司 董事、高级管理人员 ...